Pharmacogenetic Testing of Cytochrome P450 Metabolizing Enzymes in 28-Year-Old Man with Treatment-Resistant Schizophrenia
Open Access
- 15 May 2022
- journal article
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in Personalized Psychiatry and Neurology
- Vol. 2 (1), 81-88
- https://doi.org/10.52667/2712-9179-2022-2-1-81-88
Abstract
Schizophrenia is a common and socially significant mental disorder that requires long-term use of antipsychotics (APs). Long-term use of APs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of APs metabolism by cytochrome P450 enzymes. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing AP-induced ADRs. Our experience of using PGx to search for low-functional and non-functional single nucleotide variants (SNVs) / polymorphisms of the CYP1A2, CYP2C9, CYP3A4, CYP3A5 and CYP2D6) genes encoding cytochrome P450 enzymes involved in APs metabolism demonstrates the importance of this new personalized approach to the choice of APs and its dosing in patients with pharmacogenetic profile poor metabolizer. The main purpose of the case report is to present the experience of using PGx in a 28-year-old patient with treatment-resistant schizophrenia and a medical history of AP-induced ADRs.Keywords
This publication has 12 references indexed in Scilit:
- Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian FederationVestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery), 2020
- Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamicsZhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2020
- Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiologyNeuropharmacology, 2019
- Pharmacogenetics of schizophrenia in real clinical practice: a clinical caseNeurology, Neuropsychiatry, Psychosomatics, 2018
- The Pharmacogenomics Journal, 2017
- Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6Pharmacogenomics, 2017
- Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugsCurrent Drug Metabolism, 2016
- Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4Current Drug Metabolism, 2008
- Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityThe Pharmacogenomics Journal, 2004
- Cytochrome P450 Phenotyping/Genotyping in Patients Receiving AntipsychoticsClinical Pharmacokinetics, 2002